Гинекология | |
Obstetric risks of chemotherapy during pregnancy | |
Yu E Dobrokhotova1  E I Borovkova1  | |
[1] N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation; | |
关键词: pregnancy; cancer; chemotherapy; defects developmental; teratogenic effect; embryotoxicity; metastases; delay fetal growth; | |
DOI : 10.26442/20795696.2018.6.180064 | |
来源: DOAJ |
【 摘 要 】
During the first 4 weeks of gestation, the embryo is not yet differentiated and exposure to chemotherapy occurs the all-or-nothing principle. Most vulnerable to chemotherapy is the period from 5 to 10 weeks of pregnancy, the use of 1 cytostatic increases the risk of malformations in the hearth up to 10%, and a few - up to 25%. Prescription of therapy after 12 weeks is not associated with the risk of malformations. Development, but leads to delayed growth of the fetus and pancytopenia in newborns in 30%. Probability of a metostatic lesion the placenta and fetus is extremely low and is described primarily for hematogenous tumors. The course of treatment must be completed in 3 weeks. Before giving birth.
【 授权许可】
Unknown